0000899243-20-017002.txt : 20200618 0000899243-20-017002.hdr.sgml : 20200618 20200618083356 ACCESSION NUMBER: 0000899243-20-017002 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200617 FILED AS OF DATE: 20200618 DATE AS OF CHANGE: 20200618 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SELBY NORMAN C CENTRAL INDEX KEY: 0001192613 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-31141 FILM NUMBER: 20971297 MAIL ADDRESS: STREET 1: 205 WOOD ROAD CITY: MT. KISCO STATE: NY ZIP: 10549 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: INFINITY PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001113148 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330655706 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 BUSINESS PHONE: 6174531000 MAIL ADDRESS: STREET 1: 1100 MASSACHUSETTS AVENUE STREET 2: FLOOR 4 CITY: CAMBRIDGE STATE: MA ZIP: 02138 FORMER COMPANY: FORMER CONFORMED NAME: INFINITY PHARMACEUTICALS, INC./NEW/ DATE OF NAME CHANGE: 20060913 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY PARTNERS INTERNATIONAL INC DATE OF NAME CHANGE: 20000428 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-06-17 0 0001113148 INFINITY PHARMACEUTICALS, INC. INFI 0001192613 SELBY NORMAN C C/O INFINITY PHARMACEUTICALS, INC. 1100 MASSACHUSETTS AVENUE, FLOOR 4 CAMBRIDGE MA 02138 1 0 0 0 Stock Option (right to buy) 0.92 2020-06-17 4 A 0 30000 0.00 A 2030-06-16 Common Stock 30000 30000 D Stock Option (right to buy) 0.92 2020-06-17 4 A 0 10000 0.00 A 2030-06-16 Common Stock 10000 10000 D The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as a director of the issuer. The option vests over a period of one year in equal quarterly installments beginning at the end of the first quarter after the date of grant, provided that the holder continues to serve as Lead Independent Director of the issuer's Board of Directors. /s/ Norman Selby 2020-06-18